Neorecormon Market Report 2026

Neorecormon Market Overview

• The Neorecormon market growth in the historic period has been driven by increasing incidence of chronic kidney disease, rising chemotherapy-related anemia cases • Market expansion is supported by increasing aging population with anemia risk, rising demand for long-term anemia therapies • Growth Driver: Rising Prevalence Of Chronic Kidney Disease (CKD) Driving Market Growth Due To Increasing Demand For Erythropoiesis-Stimulating Agents • North America was the largest region in 2025.

What Is Covered Under Neorecormon Market?

Neorecormon is a biopharmaceutical medication used to treat anemia caused by chronic kidney disease, chemotherapy, or other conditions that affect red blood cell production. It works as an erythropoietin-stimulating agent, promoting the production of red blood cells to improve oxygen delivery throughout the body. The main types of formulations in neorecormon include injectable solutions and pre-filled syringes. Injectable solutions are medications that are administered directly into the body through a needle or syringe, and neorecormon, in its injectable solution form, is used to treat anemia in patients with chronic kidney disease (CKD), stimulating the production of red blood cells and improving oxygen delivery throughout the body. The indications are categorized into anemia due to chronic kidney disease (CKD), anemia in cancer patients, anemia associated with other conditions for end user patients, such as adult patients, pediatric patients with distribution channels, including hospitals, specialty clinics, retail pharmacies, and online pharmacies.

What Is The Neorecormon Market Growth Forecast?

The growth in the forecast period can be attributed to increasing aging population with anemia risk, rising demand for long-term anemia therapies, expansion of biologic drug accessibility, growing focus on patient quality of life, increasing use of biosimilar-compatible treatment pathways. Major trends in the forecast period include increasing use of erythropoiesis-stimulating agents, growing demand for anemia management in ckd patients, rising adoption of biologic injectables, expansion of oncology-related anemia treatments, enhanced focus on hemoglobin optimization.

What Are The Drivers Of The Neorecormon Market?

The rising prevalence of chronic kidney disease (CKD) is expected to propel the neorecormon market going forward. Chronic kidney disease (CKD) is a progressive condition in which kidney function gradually declines, often leading to anemia due to reduced erythropoietin production. The rise in CKD cases is driven by factors such as an aging population and lifestyle-related diseases. Neorecormon is essential for individuals with chronic kidney disease (CKD) to manage and improve their quality of life by addressing anemia-related conditions that commonly develop as the disease progresses. For instance, in June 2023, according to the report published by Kidney Research UK, a UK-based non-profit organization, approximately 7.2 million people in the UK are living with chronic kidney disease, representing over 10% of the population. Of these, 3.25 million are in the advanced stages of the disease, while an additional 3.9 million are in the early stages. Further, the number of individuals affected by chronic kidney disease is projected to rise to 7.61 million by 2033. Therefore, the rising prevalence of chronic kidney disease (CKD) will drive the neorecormon industry. The increasing healthcare expenditures are anticipated to propel the growth of the neorecormon market going forward. Healthcare expenditures refer to the total amount spent on healthcare-related services, products, and activities within a specified period, typically on an individual, community, national, or global level. Increasing healthcare expenditures are driven by factors such as the rising prevalence of chronic diseases, an aging population, advancements in medical technology, and growing demand for more advanced treatments and healthcare services. Increasing healthcare expenditures enhances access to treatments such as neorecormon by increasing insurance coverage, reducing patient costs, and improving funding for anemia management programs. This fosters early diagnosis, wider adoption, and market expansion, especially in emerging economies. For instance, in May 2023, the Office for National Statistics, a UK-based statistics authority, in 2023, healthcare expenditure in the UK was approximately $367 billion (£292 billion), reflecting an increase of 5.6%. Additionally, long-term health and social care expenditure rose by 2.8% in real terms in 2022. Therefore, increasing healthcare expenditure will drive the neorecormon industry. The growing aging population is projected to fuel the neorecormon market growth going forward. Aging is a natural process marked by a gradual decline in physiological functions, making individuals more susceptible to chronic conditions such as cancer and kidney diseases, which often result in anemia. The aging population is expanding with advancements in healthcare, increased life expectancy, and declining birth rates. Neorecormon, an erythropoiesis-stimulating agent (ESA), is crucial in managing anemia by boosting red blood cell production, improving energy levels, and enhancing treatment outcomes for elderly patients. For instance, in February 2025, according to the World Health Organization, a Switzerland-based international public health organization, global life expectancy at birth reached 73.3 years in 2024 and the number of people aged 60 and older worldwide is projected to rise from 1.1 billion in 2023 to 1.4 billion by 2030. Therefore, the growing aging population will drive the neorecormon industry.

Key Players In The Global Neorecormon Market

Major companies operating in the neorecormon market are F. Hoffmann-La Roche Ltd.

What Defines the Neorecormon Market?

The neorecormon market consists of sales of erythropoietin-stimulating agents in formulations such as vials, cartridges, and ampoules. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neorecormon Market Report 2026?

The neorecormon market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neorecormon industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.